Ethical priorities for international collaborative adaptive platform trials for public health emergencies

Katharine Wright; Joseph Ali; Alun Davies; Paul Glasziou; Nina Gobat; Tanja Kuchenmüller; Katherine Littler; Chelsea Modlin; Lee-Anne Pascoe; Andreas Reis; Jerome Amir Singh

doi:10.1136/bmjgh-2023-012930

Ethical priorities for international collaborative adaptive platform trials for public health emergencies

Katharine Wright
, Joseph Ali
, Alun Davies
, Paul Glasziou
, Nina Gobat
, Tanja Kuchenmüller
, Katherine Littler
, Chelsea Modlin
, Lee-Anne Pascoe
, Andreas Reis
, Jerome Amir Singh

Institute for Evidence-Based Healthcare

Research output: Contribution to journal › Comment/debate/opinion › Research › peer-review

4 Citations (Scopus)

86 Downloads (Pure)

Abstract

Rapidly produced evidence on effective medical counter measures is critical for responding to health emergencies caused by (re-)emerging infectious diseases.

Adaptive platform trials played a significant role in the global research response to COVID-19 and are likely to be increasingly used in the future, both in emergency and non-emergency contexts.

We call attention to a number of ethical considerations that should influence the development and future implementation of large-scale multicountry adaptive platform studies.

Original language	English
Article number	e012930
Pages (from-to)	1-4
Number of pages	4
Journal	BMJ Global Health
Volume	8
Issue number	7
DOIs	https://doi.org/10.1136/bmjgh-2023-012930
Publication status	Published - 31 Jul 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1136/bmjgh-2023-012930Licence: CC BY-NC

Ethical priorities for international collaborative adaptive platform trials for public health emergenciesFinal published version, 525 KBLicence: CC BY-NC

Cite this

@article{7125ea00898c41668f0422bf47755901,

title = "Ethical priorities for international collaborative adaptive platform trials for public health emergencies",

abstract = "Rapidly produced evidence on effective medical counter measures is critical for responding to health emergencies caused by (re-)emerging infectious diseases. Adaptive platform trials played a significant role in the global research response to COVID-19 and are likely to be increasingly used in the future, both in emergency and non-emergency contexts. We call attention to a number of ethical considerations that should influence the development and future implementation of large-scale multicountry adaptive platform studies.",

author = "Katharine Wright and Joseph Ali and Alun Davies and Paul Glasziou and Nina Gobat and Tanja Kuchenm{\"u}ller and Katherine Littler and Chelsea Modlin and Lee-Anne Pascoe and Andreas Reis and Singh, \{Jerome Amir\}",

note = "Funding Information: This work was supported by the Wellcome Trust (214711, https://doi.org/10.35802/214711and221719 , https://doi.org/10.35802/221719 ).",

year = "2023",

month = jul,

day = "31",

doi = "10.1136/bmjgh-2023-012930",

language = "English",

volume = "8",

pages = "1--4",

journal = "BMJ Global Health",

issn = "2059-7908",

publisher = "BMJ Publishing Group",

number = "7",

}

TY - JOUR

T1 - Ethical priorities for international collaborative adaptive platform trials for public health emergencies

AU - Wright, Katharine

AU - Ali, Joseph

AU - Davies, Alun

AU - Glasziou, Paul

AU - Gobat, Nina

AU - Kuchenmüller, Tanja

AU - Littler, Katherine

AU - Modlin, Chelsea

AU - Pascoe, Lee-Anne

AU - Reis, Andreas

AU - Singh, Jerome Amir

N1 - Funding Information: This work was supported by the Wellcome Trust (214711, https://doi.org/10.35802/214711and221719 , https://doi.org/10.35802/221719 ).

PY - 2023/7/31

Y1 - 2023/7/31

N2 - Rapidly produced evidence on effective medical counter measures is critical for responding to health emergencies caused by (re-)emerging infectious diseases. Adaptive platform trials played a significant role in the global research response to COVID-19 and are likely to be increasingly used in the future, both in emergency and non-emergency contexts. We call attention to a number of ethical considerations that should influence the development and future implementation of large-scale multicountry adaptive platform studies.

AB - Rapidly produced evidence on effective medical counter measures is critical for responding to health emergencies caused by (re-)emerging infectious diseases. Adaptive platform trials played a significant role in the global research response to COVID-19 and are likely to be increasingly used in the future, both in emergency and non-emergency contexts. We call attention to a number of ethical considerations that should influence the development and future implementation of large-scale multicountry adaptive platform studies.

UR - https://www.scopus.com/pages/publications/85167433467

U2 - 10.1136/bmjgh-2023-012930

DO - 10.1136/bmjgh-2023-012930

M3 - Comment/debate/opinion

C2 - 37524503

SN - 2059-7908

VL - 8

SP - 1

EP - 4

JO - BMJ Global Health

JF - BMJ Global Health

IS - 7

M1 - e012930

ER -

Ethical priorities for international collaborative adaptive platform trials for public health emergencies

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this